{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent%2C+Refractory%2C+or+High+Risk+Leukemias&page=6", "query": { "condition": "Recurrent, Refractory, or High Risk Leukemias", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 137, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent%2C+Refractory%2C+or+High+Risk+Leukemias&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent%2C+Refractory%2C+or+High+Risk+Leukemias&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T03:35:36.707Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02319369", "title": "Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Milademetan", "type": "DRUG" }, { "name": "AZA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2014-11-25", "completion_date": "2020-08-21", "has_results": true, "last_update_posted_date": "2021-10-11", "last_synced_at": "2026-10-14T03:35:36.707Z", "location_count": 5, "location_summary": "Duarte, California • San Francisco, California • Fairway, Kansas + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Buffalo", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02319369" }, { "nct_id": "NCT04375631", "title": "CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Mixed Phenotype Acute Leukemia", "Refractory Myelodysplastic Syndrome", "Refractory Acute Leukemia of Ambiguous Lineage", "Refractory Acute Undifferentiated Leukemia" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Mycophenolate Sodium", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2020-12-03", "completion_date": "2027-03-17", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-14T03:35:36.707Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04375631" }, { "nct_id": "NCT00397579", "title": "DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Blastic Plasmacytoid Dendritic Cell Neoplasm" ], "interventions": [ { "name": "DT388IL3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-05", "completion_date": "2017-07-27", "has_results": true, "last_update_posted_date": "2019-04-23", "last_synced_at": "2026-10-14T03:35:36.707Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00397579" }, { "nct_id": "NCT04047641", "title": "Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Blasts 20 Percent or More of Bone Marrow Nucleated Cells", "High Risk Myelodysplastic Syndrome", "Recurrent Acute Biphenotypic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent High Risk Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory High Risk Myelodysplastic Syndrome" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Quizartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2019-10-22", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-14T03:35:36.707Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04047641" }, { "nct_id": "NCT00027937", "title": "Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "56 Years", "sex": "ALL", "summary": "Up to 56 Years" }, "enrollment_count": null, "start_date": "2001-08", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2010-05-14", "last_synced_at": "2026-10-14T03:35:36.707Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027937" }, { "nct_id": "NCT03896269", "title": "CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Blasts 10-19 Percent of Bone Marrow Nucleated Cells", "Blasts More Than 5 Percent of Bone Marrow Nucleated Cells", "High Risk Chronic Myelomonocytic Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent High Risk Myelodysplastic Syndrome", "Refractory Chronic Myelomonocytic Leukemia", "Refractory High Risk Myelodysplastic Syndrome" ], "interventions": [ { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2019-05-14", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-14T03:35:36.707Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896269" }, { "nct_id": "NCT01444742", "title": "Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myeloproliferative Diseases" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2011-11-16", "completion_date": "2017-01-29", "has_results": true, "last_update_posted_date": "2018-07-03", "last_synced_at": "2026-10-14T03:35:36.707Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01444742" }, { "nct_id": "NCT05672251", "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia", "Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Loncastuximab Tesirine", "type": "BIOLOGICAL" }, { "name": "Mosunetuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2024-01-02", "completion_date": "2029-08-24", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-14T03:35:36.707Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05672251" }, { "nct_id": "NCT00047021", "title": "Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 3, "start_date": "2001-11", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-10-14T03:35:36.707Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047021" }, { "nct_id": "NCT00002481", "title": "Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "St. Luke's Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "1990-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-14T03:35:36.707Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002481" } ] }